Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.44 |
| ▸ | TACR1 | P25103 | 7/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26833180 | 0.86 | CFD (0.42) | FAPTACR1CFDDPP8DPP7 | |
| SCHEMBL24666350 | 0.86 | CFD (0.42) | FAPTACR1CFDDPP8DPP7 | |
| SCHEMBL29230668 | 0.86 | PSMB9 (0.44) | FAPTACR1CFDPSMB9 | |
| SCHEMBL24666462 | 0.86 | PSMB9 (0.44) | FAPTACR1CFDPSMB9 | |
| SCHEMBL29231340 | 0.86 | CFD (0.47) | TACR1CFDDPP8DPP7AADAT | |
| SCHEMBL24665904 | 0.86 | CFD (0.47) | TACR1CFDDPP8DPP7AADAT | |
| SCHEMBL24666612 | 0.84 | TACR1 (0.46) | FAPTACR1CFDDPP8DPP7 | |
| SCHEMBL24666348 | 0.82 | FAP (0.41) | FAPTACR1CFDDPP8DPP7 | |
| SCHEMBL30874857 | 0.82 | TACR1 (0.55) | FAPTACR1CFDDPP8DPP7 | |
| SCHEMBL24666756 | 0.82 | TACR1 (0.55) | FAPTACR1CFDDPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | FAP 4161/4885TACR1 4794/4885CFD 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.